57 citations
,
August 2003 in “British Journal of Dermatology”
This study found that daily use of 1% pyrithione zinc shampoo modestly improved hair growth over 26 weeks, although these effects were less than those of 5% minoxidil.
In this case report, microneedling combined with PRP improved hair density and thickness in a 40-year-old man with androgenic alopecia, without side effects, suggesting it as a therapeutic option for those avoiding long-term pharmacotherapy.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)”
This case report details a 28-year-old male with early-stage androgenetic alopecia who experienced significant hair density and thickness improvements following a three-month platelet-rich plasma therapy regimen, supporting its potential efficacy in similar cases.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)”
In this case report, a 28-year-old male with androgenetic alopecia experienced significant improvement in hair density and shaft thickness after a three-month platelet-rich plasma therapy regimen, supporting existing literature on PRP's efficacy for early-to-moderate hair loss.
Hair regrowth typically levels out after several months of treatment with finasteride, dutasteride, and minoxidil, with many users experiencing stabilization rather than significant regrowth. Starting treatment early is crucial, as regrowth is rare beyond Norwood 3 without additional interventions like hair transplants.
The user has been on finasteride for 17 months to treat hair loss, with some improvement in the crown but still experiencing significant shedding. They are considering if finasteride alone is sufficient and are hesitant to use minoxidil due to a pre-existing condition, while another person suggests trying dutasteride.
The user has been using Morr-F Aqua 5% (minoxidil) once daily for over three months to address male pattern baldness and is seeking feedback on their progress. They are unsure if the current dosage is sufficient and whether the aqueous base is effective compared to other versions.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.